Zevra Therapeutics to Present at Canaccord Genuity's 44th Annual Growth Conference
Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline
Express News | Cantor Fitzgerald Reiterates Overweight on Zevra Therapeutics
Why Kellanova Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
FDA Panel Backs Zevra's Arimoclomol For Rare Genetic Disorder, Analyst Highlights Balanced Portfolio Of Marketed Products And Pipeline Assets Focused On Rare Diseases
Top Premarket Gainers
Zevra Shares Rally Premarket After FDA Panel Backs Arimoclomol
Zevra Therapeutics Analyst Ratings
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Raises Target Price to $18
Buy Rating Affirmed for Zevra Therapeutics Amid Strong AdCom Support and High Market Potential
Express News | Zevra Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $18 From $15
Reported Friday, Zevra Therapeutics Gains FDA Panel Support For Arimoclomol In Treating Niemann-Pick Disease Type C
Zevra Wins FDA AdCom Backing for Rare Disease Therapy Arimoclomol
Express News | Trading Halt: Halt Status Updated at 6:15:00 PM ET: Quotation Resumption: News and Resumption Times
Express News | Zevra Therapeutics Inc: Arimoclomol Nda Has Been Assigned a Prescription Drug User Fee Act Action Date of Sept 21, 2024
FDA Advisory Committee Votes Favorably That the Data Support Arimoclomol as Effective Treatment for Patients With Niemann-Pick Disease Type C
Zevra Halted Ahead of FDA AdCom on Niemann-Pick Drug -- Market Talk
Express News | Trading Halt: Halted at 6:55:00 A.m. ET - Trading Halt: Halt News Pending
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $18
Buy Rating Affirmed for Zevra Therapeutics Amidst Positive Developments for NPC Drug Arimoclomol